Related Experiment Video
Updated: Jul 28, 2026
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Fanconi anemia: myelodysplasia as a predictor of outcome
B P Alter1, J P Caruso, R A Drachtman
1Division of Pediatric Hematology/Oncology, University of Texas Medical Branch, Galveston, TX, USA.
Abstract:
The adverse potential of the development of myelodysplastic syndrome (MDS) in Fanconi anemia (FA) was examined in a retrospective study of 41 FA patients who had bone marrow morphology and chromosomes reviewed by a single group. Thirty-three patients had adequate cytogenetic studies, and 16 (48%) had one or more abnormal studies: nine initially, and seven more on follow-up. Cytogenetic clonal variation was frequent, including disappearance of clones, clonal evolution, and appearance of new clones. The estimated five-year survival with a cytogenetic clone is 0.40, compared to 0.94 without a clone. Morphologic myelodysplasia (MDS), independent of a cytogenetic clone, was found in 13/41 patients (32%). The estimated five-year survival with MDS is 0.09, versus 0.92 without MDS. Leukemia developed in three patients whose initial cytogenetic clones prior to leukemia were t(1;18), t(5;22) and monosomy 7; the one with t(1;18) also had MDS. Our results focus on marrow morphology, and suggest that morphologic MDS may be more important than classical cytogenetics in prediction of an adverse outcome.
Insights
Myelodysplastic syndrome (MDS) in Fanconi anemia (FA) patients is linked to poor survival. Morphologic MDS showed a stronger adverse outcome prediction than cytogenetic abnormalities in this study.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Fanconi anemia (FA) is a rare genetic disorder associated with bone marrow failure.
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
Purpose of the Study:
- To investigate the prognostic significance of morphologic myelodysplasia (MDS) and cytogenetic abnormalities in Fanconi anemia (FA) patients.
- To determine the impact of these findings on patient survival.
Main Methods:
- Retrospective analysis of 41 FA patients.
- Review of bone marrow morphology and cytogenetics by a single expert group.
- Analysis of cytogenetic clonal variation and morphologic MDS presence.
Main Results:
- Cytogenetic abnormalities were found in 48% of patients with adequate studies.
- Morphologic MDS was present in 32% of patients, independent of cytogenetic clones.
- Five-year survival was significantly lower for patients with cytogenetic clones (0.40) and morphologic MDS (0.09) compared to those without.
Conclusions:
- Morphologic myelodysplasia (MDS) appears to be a more critical predictor of adverse outcomes in Fanconi anemia (FA) than traditional cytogenetics.
- Early identification and monitoring of morphologic changes are crucial for managing FA patients.
- Further research is warranted to elucidate the mechanisms underlying MDS development in FA.
